Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.
1. A method for expanding tumor infiltrating lymphocytes (TILs) into a therapeutic population of TILs, the method comprising:
(a) obtaining a first population of TILs from a tumor resected from a patient by processing a tumor sample resected from the patient into a tumor digest;
(b) cryopreserving the tumor digest from step (a) to produce a cryopreserved tumor digest;
(c) performing a first expansion by (i) thawing the cryopreserved tumor digest to obtain a thawed tumor digest comprising the first population of TILs and (ii) culturing the thawed tumor digest comprising the first population of TILs in a cell culture medium comprising IL-2, and optionally OKT-3, to produce a second population of TILs, wherein the first expansion is performed in a closed container providing a first gas-permeable surface area, wherein the first expansion is performed for about 3-14 days to obtain the second population of TILs, wherein the transition from step (b) to step (c) occurs without opening the system;
(d) performing a second expansion by supplementing the cell culture medium of the second population of TILs with additional IL-2, optionally OKT-3, and antigen presenting cells (APCs), to produce a third population of TILs, wherein the second expansion is performed for about 7-14 days to obtain the third population of TILs, wherein the second expansion is performed in a closed container providing a second gas-permeable surface area, and wherein the transition from step (c) to step (d) occurs without opening the system; and
(e) harvesting the third population of TILs, wherein the harvested third population of TILs is a therapeutic population of TILs, and wherein the transition from step (d) to step (e) occurs without opening the system.
2. The method of claim 1 , wherein in step (a) the tumor resected from the patient is processed into a tumor digest in an enzymatic media.
3. The method of claim 2 , wherein the enzymatic media comprises a mixture of enzymes.
4. The method of claim 3 , wherein the mixture of enzymes comprises a collagenase.
5. The method of claim 3 , wherein the mixture of enzymes comprises a DNase.
6. The method of claim 3 , wherein the mixture of enzymes comprises a collagenase and a DNase.
7. The method of claim 1 , wherein in step (e) the third population of TILs is harvested using a cell processing system.
8. The method of claim 7 , wherein the cell processing system is a LOVO cell processing system.
9. The method of claim 1 , wherein the method further comprises performing the step of:
(f) transferring the therapeutic population of TILs obtained from step (e) to an infusion bag, wherein the transition from step (e) to step (f) occurs without opening the system.
10. The method of claim 9 , wherein the method further comprises cryopreserving the infusion bag.
11. The method of claim 1 , wherein the first expansion is performed within a period of about 7 days.
12. The method of claim 1 , wherein the second expansion is performed within a period of about 14 days.
13. The method of claim 1 , wherein the first expansion is performed within a first period of about 7 days and the second expansion is performed within a second period of about 14 days.
14. The method of claim 1 , wherein step (c) through step (d) are performed within a period of about 21 days.
15. A method for expanding tumor infiltrating lymphocytes (TILs) into a therapeutic population of TILs, the method comprising:
(a) performing a first expansion by (i) thawing a cryopreserved tumor digest comprising a first population of TILs from a tumor that was resected from a subject, digested after the resection, and cryopreserved after the digestion, and (ii) culturing the first population of TILs in a cell culture medium comprising IL-2, and optionally OKT-3, to produce a second population of TILs, wherein the first expansion is performed in a closed container providing a first gas-permeable surface area, wherein the first expansion is performed for about 3-14 days to obtain the second population of TILs;
(b) performing a second expansion by supplementing the cell culture medium of the second population of TILs with additional IL-2, optionally OKT-3, and antigen presenting cells (APCs), to produce a third population of TILs, wherein the second expansion is performed for about 7-14 days to obtain the third population of TILs, wherein the second expansion is performed in a closed container providing a second gas-permeable surface area, and wherein the transition from step (a) to step (b) occurs without opening the system; and
(c) harvesting the third population of TILs, wherein the harvested third population of TILs is a therapeutic population of TILs, and wherein the transition from step (b) to step (c) occurs without opening the system.
16. The method of claim 15 , wherein in step (a)(i) the resected tumor was subjected to digestion in an enzymatic media.
17. The method of claim 16 , wherein the enzymatic media comprised a mixture of enzymes.
18. The method of claim 17 , wherein the mixture of enzymes comprised a collagenase.
19. The method of claim 17 , wherein the mixture of enzymes comprised a DNase.
20. The method of claim 17 , wherein the mixture of enzymes comprised a collagenase and a DNase.
21. The method of claim 15 , wherein in step (c) the third population of TILs is harvested using a cell processing system.
22. The method of claim 21 , wherein the cell processing system is a LOVO cell processing system.
23. The method of claim 15 , wherein the method further comprises performing the step of:
(d) transferring the therapeutic population of TILs obtained from step (c) to an infusion bag, wherein the transition from step (c) to step (d) occurs without opening the system.
24. The method of claim 23 , wherein the method further comprises cryopreserving the infusion bag.
25. The method of claim 15 , wherein the first expansion is performed within a period of about 7 days.
26. The method of claim 15 , wherein the second expansion is performed within a period of about 14 days.
27. The method of claim 15 , wherein the first expansion is performed within a first period of about 7 days and the second expansion is performed within a second period of about 14 days.
28. The method of claim 15 , wherein step (a) through step (b) are performed within a period of about 21 days.